Anti-inflammatory effects of low molecular weight heparin derivative in a rat model of carrageenan-induced pleurisy.
Low molecular weight heparin derivatives are characterized by low anti-coagulant activity and marked anti-inflammatory effects that allow for these molecules to be viewed as a new class of non-steroidal anti-inflammatory drugs (NSAIDs). We show here that K5NOSepiLMW, an O-sulphated heparin-like semi-synthetic polymer of the D-glucuronic acid-N-acetyleparoson disaccharide unit with low molecular weight, has marked anti-inflammatory effects in a rat model of acute inflammation, the carrageenan-induced pleurisy, commonly used to test NSAID efficacy. A 30-min. pre-treatment with K5NOSepiLMW (0.1, 0.5 and 1 mg/kg b.wt., given intrapleurally) attenuated the recruitment of leucocytes in the lung tissue and the pleural exudate, inhibited the induction of inducible nitric oxide synthase and cyclooxygenase-2 (COX-2), thereby abating the generation of nitric oxide and pro-inflammatory prostaglandins such as PgE(2) and PGF(1alpha), reduced the inflammation-induced nitroxidative lung tissue injury, as shown by tissue thiobarbituric acid-reactive substances and nitrotyrosine, and blunted the local generation of cytokines such as interleukin-1beta and tumour necrosis factor-alpha. All these parameters were markedly increased by intrapleural carrageenan in the absence of any pre-treatment. The anti-inflammatory action of K5NOSepiLMW is specific, as judged by the lack of therapeutic effects of B4/110, a biologically inactive cognate polysaccharide, given in the place of the authentic molecule. Moreover, K5NOSepiLMW showed similar effects as celecoxib (1 mg/kg b.wt), a COX-2 inhibitor and well-known NSAID. This study provides further insight into the mechanisms underlying the beneficial effects of heparin derivatives in inflammation and identifies K5NOSepiLMW as a novel, promising anti-inflammatory drug.
Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy.
Matteo
M
Ceccarelli
Daniele
D
Bani
Lorenzo
L
Cinci
Silvia
S
Nistri
Caterina
C
Uliva
Elena
E
Ragazzo
Alfredo
A
Vannacci
Marco
M
Manoni
Anna Maria
AM
Gori
Rosanna
R
Abbate
Gian Franco
GF
Gensini
Emanuela
E
Masini
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002351:Carrageenan / Q000633:toxicity*; D004195:Disease Models, Animal; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology*; D007150:Immunohistochemistry; D008297:Male; D010998:Pleurisy / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology*; D051381:Rats; D017208:Rats, Wistar; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D006495:Heparin, Low-Molecular-Weight; D017392:Thiobarbituric Acid Reactive Substances; D002351:Carrageenan